Fuji Pharma Co., Ltd. (TYO:4554)

Fuji Pharma Balance Sheet

Financials in millions JPY. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cash & Equivalents	3,696	4,585	2,324	3,546	10,199	12,041
Cash & Short-Term Investments	3,696	4,585	2,324	3,546	10,199	12,041
Cash Growth	71.03%	97.29%	-34.46%	-65.23%	-15.30%	41.76%
Accounts Receivable	19,868	18,426	16,304	12,527	11,866	11,700
Other Receivables	217	453	216	134	118	8
Receivables	20,085	18,879	16,520	12,661	11,984	11,708
Inventory	20,972	18,005	19,371	15,823	12,006	10,680
Other Current Assets	840	999	899	2,697	645	546
Total Current Assets	45,593	42,468	39,114	34,727	34,834	34,975
Property, Plant & Equipment	20,887	20,911	20,547	18,762	14,392	12,767
Long-Term Investments	14,999	13,036	14,702	10,211	11,265	10,131
Goodwill	-	88	412	691	865	1,144
Other Intangible Assets	12,226	12,356	10,081	9,713	1,532	1,755
Long-Term Deferred Tax Assets	554	1,139	475	1,432	1,349	1,189
Other Long-Term Assets	1	2	1	2	2	1
Total Assets	94,260	90,000	85,332	75,538	64,239	61,962
Accounts Payable	7,590	4,140	5,672	6,249	5,713	3,680
Accrued Expenses	395	560	883	990	982	438
Short-Term Debt	17,300	15,300	11,300	8,300	7,000	1,000
Current Portion of Long-Term Debt	6,750	7,100	5,210	2,440	1,840	1,640
Current Portion of Leases	569	569	514	377	681	516
Current Income Taxes Payable	275	1,567	484	444	823	460
Other Current Liabilities	5,395	6,561	5,708	5,175	3,153	3,270
Total Current Liabilities	38,274	35,797	29,771	23,975	20,192	11,004
Long-Term Debt	1,233	1,583	8,683	11,193	6,633	7,590
Long-Term Leases	4,560	4,702	3,241	2,259	2,508	1,444
Other Long-Term Liabilities	229	227	598	541	570	416
Total Liabilities	46,502	44,439	44,156	39,734	31,560	22,002
Common Stock	3,847	3,799	3,799	3,799	3,799	3,799
Additional Paid-In Capital	4,454	4,406	4,409	4,409	4,409	5,841
Retained Earnings	34,699	34,256	29,082	26,546	24,628	30,424
Treasury Stock	-498	-505	-567	-579	-590	-68
Comprehensive Income & Other	5,253	3,602	4,451	1,627	432	-38
Total Common Equity	47,755	45,558	41,174	35,802	32,678	39,958
Minority Interest	3	3	2	2	1	2
Shareholders' Equity	47,758	45,561	41,176	35,804	32,679	39,960
Total Liabilities & Equity	94,260	90,000	85,332	75,538	64,239	61,962
Total Debt	30,412	29,254	28,948	24,569	18,662	12,190
Net Cash (Debt)	-26,716	-24,669	-26,624	-21,023	-8,463	-149
Net Cash Per Share	-1098.75	-1014.74	-1095.58	-865.39	-315.00	-4.78
Filing Date Shares Outstanding	24.38	24.31	24.3	24.29	24.29	31.16
Total Common Shares Outstanding	24.38	24.31	24.3	24.29	24.29	31.16
Working Capital	7,319	6,671	9,343	10,752	14,642	23,971
Book Value Per Share	1958.80	1873.87	1694.21	1473.66	1345.50	1282.41
Tangible Book Value	35,529	33,114	30,681	25,398	30,281	37,059
Tangible Book Value Per Share	1457.32	1362.03	1262.45	1045.42	1246.81	1189.37
Order Backlog	-	1,697	1,672	1,313	213	115

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.